Coagulation factor assays from HYPHEN BioMed covering both immunodepleted plasma substrates for one-stage clotting assays and BIOPHEN™ chromogenic activity kits for specific factor quantification.
Factor assays are essential for diagnosing congenital bleeding disorders including hemophilia A (FVIII), hemophilia B (FIX), hemophilia C (FXI), Factor VII deficiency, Factor X deficiency, and Factor XIII deficiency, as well as monitoring factor concentrate therapy including extended half-life products.
Chromogenic methods provide assay results independent of lupus anticoagulants and other clotting interferences — the recommended approach for FVIII monitoring in patients on emicizumab (Hemlibra®).
| Reference | Product Name | Price | ||
|
|
ARK032A
|
ZYMUTEST™ Factor IX — FIX Antigen ELISA | $768.00 | |
|
|
A221812
|
BIOPHEN™ FIXa — Activated Factor IX Activity Assay | $260.00 | |
|
|
A221705
|
BIOPHEN™ Factor X — FX Activity Chromogenic Assay (RVV Method) | $509.00 | |
|
|
ARK033A
|
ZYMUTEST™ Factor X — FX Antigen ELISA | $988.00 | |
|
|
A220412
|
BIOPHEN™ Factor XIa — Activated FXI Activity Chromogenic Assay | $593.00 | |
|
|
A227005-RUO
|
BIOPHEN™ Factor XIII — FXIII Activity Chromogenic Assay | $622.00 | |
|
|
A221801-RUO
|
BIOPHEN™ Factor IX Chromogenic Assay (2 × 1 mL) | $411.00 | |
|
|
A221802-RUO
|
BIOPHEN™ Factor IX Chromogenic Assay (2 × 2.5 mL) | $593.00 | |
|
|
A221801-CAN
|
BIOPHEN™ Factor IX Chromogenic Assay (2 × 1 mL) | $394.00 | |
|
|
ADP050K-CAN
|
Factor IX Deficient Plasma (6 × 1 mL) — <1% Residual | $368.00 | |
|
|
A227102-RUO
|
BIOPHEN™ FVIII Variant — Emicizumab-Insensitive FVIII Assay (Bovine FX) | $461.00 |